Novosys Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 6 Year, 4 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.82 Cr
- Satisfied Charges ₹ 2.00 Cr
- Revenue Growth 31.06%
- Profit Growth 115.05%
- Ebitda 86.93%
- Net Worth 34.95%
- Total Assets 3.42%
About Novosys Life Sciences
Novosys Life Sciences Private Limited (NLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 February 2019 (Six years 4 days old ). Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹4.82 Cr. The company has closed loans amounting to ₹2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dayawanti and Kiran Bala serve as directors at the Company.
Company Details
- Location
Chandigarh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U85200CH2019PTC042388
- Company No.
042388
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Feb 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Novosys Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dayawanti  | Director | 19-Feb-2019 | Current |
| Kiran Bala | Director | 19-Feb-2019 | Current |
Financial Performance of Novosys Life Sciences.
Novosys Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.06% increase. The company also saw a substantial improvement in profitability, with a 115.05% increase in profit. The company's net worth Soared by an impressive increase of 34.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novosys Life Sciences?
In 2023, Novosys Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹48.20 M
₹20.00 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 4.82 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Jun 2024 | Hdfc Bank Limited | ₹4.82 Cr | Open |
| 30 Oct 2023 | Others | ₹2.00 Cr | Satisfied |
How Many Employees Work at Novosys Life Sciences?
Unlock and access historical data on people associated with Novosys Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novosys Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novosys Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
